In this episode of Market Bites, the hosts discuss three companies: Johnson & Johnson, Netflix & Burberry
In this episode of Market Bites, the hosts discuss three companies: Johnson & Johnson, Netflix, and Burberry. Johnson & Johnson has been underperforming in the market due to the expected introduction of biosimilars competition for their top-selling drug, legal challenges related to their talc powder, and regulatory challenges. Netflix, on the other hand, has seen strong growth in subscribers and revenue, with expectations of continued profitability. Burberry, however, is struggling and trading at a 14-year low. The removal of tax-free shopping in the UK, changing consumer preferences, and leadership changes have contributed to their decline. The hosts suggest caution before investing in Burberry and emphasize the importance of turning the company's fortunes around.
Takeaways
- Johnson & Johnson is facing challenges from biosimilars competition, legal issues, and regulatory changes.
- Netflix has experienced strong subscriber and revenue growth, with expectations of continued profitability.
- Burberry is struggling due to the removal of tax-free shopping, changing consumer preferences, and leadership changes.
- Investors should exercise caution before investing in Burberry and wait for signs of improvement.
- Turning a company's fortunes around often requires going back to basics and understanding consumer preferences.
Learn more about trading by visiting the eToro Academy home page where you can read reports, watch videos and sign up to our free trading course.
Your capital is at risk. Other fees apply. For more information, visit etoro.com/trading/fees. Past performance is not an indication of future results.
This communication is for information and education purposes only and should not be taken as investment advice, a personal recommendation, or an offer of, or solicitation to buy or sell, any financial instruments. This material has been prepared without taking into account any particular recipient’s investment objectives or financial situation, and has not been prepared in accordance with the legal and regulatory requirements to promote independent research. Any references to past or future performance of a financial instrument, index or a packaged investment product are not, and should not be taken as, a reliable indicator of future results. eToro makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication.